Vol 48, No 3 (2017)
Prace poglądowe / Reviews
Published online: 2017-07-01

open access

Page views 244
Article views/downloads 513
Get Citation

Connect on Social Media

Connect on Social Media

Ixazomib in patients with relapsed/refractory multiple myeloma

Krzysztof Giannopoulos12, Wiesław Wiktor Jędrzejczak3, Krzysztof Jamroziak4, Dominik Dytfeld5, Tadeusz Robak6, Andrzej Hellmann7
DOI: 10.1016/j.achaem.2017.07.002
Acta Haematol Pol 2017;48(3):160-164.

Abstract

Ixazomib is a new agent registered in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is the first oral proteasome inhibitor. Registration data show improvement in progression-free survival time (20.6 vs 14.7 months, p=0.01) but recent analysis in Asian population also in overall survival (25.8 vs 15.8 months, HR=0.419, p=0.001) what placed with lack of ixazomib incremental toxicity may implicate clinical importance of the treatment in relapsed or refractory multiple myeloma. Oral dosing of the triplet regimen may decrease the number and duration of hospitalizations that allows for better social functioning and occupational performance, and thus impacts daily disease perception.

Article available in PDF format

View PDF (Polish) Download PDF file